NSABP-B51 : A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

ThreePhase Three

18+Age Over 18

Breast<br/>CancersCancer LocationBreast
Cancers

Radiotherapy | BreastBreast

Trial Overview Read MoreRead more

This phase III trial is evaluating standard and more comprehensive radiation therapy for patients with early-stage breast cancer who have undergone surgery.
 

This trial is treating patients with breast cancer.

This is a radiotherapy trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.
  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Cooperative Group

Radiation Therapy Oncology Group

Other Non-Commercial Sponsor

NSABP Foundation Inc

Summary

Eligible patients will be randomised to receive whole breast or regional nodal radiation using IMRT or 3D-CRT once daily 5 days a week for 5 weeks. Patients will be grouped according to whether they have previously undergone a mastectomy or lumpectomy procedure. Lumpectomy patients will receive an additional radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks, following the original radiation treatment.

Recruiting Hospitals Read MoreRead more

Peter MacCallum Cancer Centre
Moorabbin
Moorabbin Research
moorabbin.research@petermac.org
03 9928 8994

Peter MacCallum Cancer Centre, Radiation Oncology
Parkville
Smitha Sithara
Smitha.sithara@petermac.org
03 8559 8771

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next